| Yancoal Australia Limited (YAL) ORDINARY FULLY PAID |
Energy |
$8,055 |
2024 Financial Results Market Release
|
20 Feb 2025 7:46PM |
$5.740 |
$6.100 |
risen by
6.27%
|
|
YAL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $6.86 billion, down from $7.78 billion in 2023.
- Operating EBITDA of $2.58 billion with a 37% margin.
- ROM coal production of 62.7 million tonnes, up 4% from 2023.
- Attributable saleable coal production of 36.9 million tonnes, up 10%.
- Final dividend declared of A$687 million or A$0.52 per share.
- 2025 production guidance: 35-39 million tonnes.
- Cash operating costs expected to be between $89-97 per tonne.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| nanollose Limited (NC6) ORDINARY FULLY PAID |
Health Care |
$20 |
Half Yearly Report and Accounts
|
20 Feb 2025 7:46PM |
$0.018 |
$0.065 |
risen by
261.11%
|
|
NC6 - Price-sensitive ASX Announcement
Full Release
Key Points
- Nanollose Limited announced a loss of $725,681 for the half-year ended 31 December 2024.
- The company's net liabilities stood at $573,932 as of 31 December 2024.
- Nanollose is focusing on commercialising its patented fibres including Nullarbor and Nufolium.
- The company shipped 110kg of Nufolium-20™ fibre for testing by Glatfelter.
- Nanollose raised $2.1 million through a capital raise to support its operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GenusPlus Group Ltd (GNP) ORDINARY FULLY PAID |
Industrials |
$647 |
Half Year Results Conference Call
|
20 Feb 2025 7:44PM |
$2.900 |
$3.590 |
risen by
23.79%
|
|
| BlueScope Steel Limited (BSL) ORDINARY FULLY PAID |
Materials |
$9,935 |
1HFY2025 Financial Results Presentation - Clarification
|
20 Feb 2025 7:44PM |
$24.550 |
$22.650 |
fallen by
7.74%
|
|
| Yancoal Australia Limited (YAL) ORDINARY FULLY PAID |
Energy |
$8,055 |
Full Year Statutory Accounts
|
20 Feb 2025 7:43PM |
$5.740 |
$6.100 |
risen by
6.27%
|
|
YAL - Price-sensitive ASX Announcement
Full Release
Key Points
- Yancoal produced 36.9 million tonnes of saleable coal in 2024.
- Cash operating costs were $93 per tonne, achieving guidance.
- Yancoal held almost $2.5 billion in cash at the end of 2024.
- The company declared a fully franked final dividend of A$687 million.
- Yancoal was included in the S&P/ASX 200 and S&P/ASX 300 Indices.
- A tragic incident resulted in a fatality at the Austar Mine.
- The company is committed to improving workplace safety and mental health.
- Efforts to enhance gender diversity on the board are underway.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Veem Ltd (VEE) ORDINARY FULLY PAID |
Industrials |
$95 |
Application for quotation of securities - VEE
|
20 Feb 2025 7:37PM |
$0.850 |
$0.695 |
fallen by
18.24%
|
|
| Yancoal Australia Limited (YAL) ORDINARY FULLY PAID |
Energy |
$8,055 |
HKEX - List of Directors
|
20 Feb 2025 7:33PM |
$5.740 |
$6.100 |
risen by
6.27%
|
|
| Vertex Minerals Limited (VTX) ORDINARY FULLY PAID |
Materials |
$53 |
Application for quotation of securities - VTX
|
20 Feb 2025 7:33PM |
$0.315 |
$0.265 |
fallen by
15.87%
|
|
| Yancoal Australia Limited (YAL) ORDINARY FULLY PAID |
Energy |
$8,055 |
Non-Executive Director appointments and resignation
|
20 Feb 2025 7:33PM |
$5.740 |
$6.100 |
risen by
6.27%
|
|
| Tivan Limited (TVN) ORDINARY FULLY PAID |
Materials |
$217 |
Notification of cessation of securities - TVN
|
20 Feb 2025 7:14PM |
$0.094 |
$0.105 |
risen by
11.70%
|
|
| Peak Minerals Limited (PUA) ORDINARY FULLY PAID |
Materials |
$53 |
Update - Proposed issue of securities - PUA
|
20 Feb 2025 7:14PM |
$0.011 |
$0.019 |
risen by
72.73%
|
|
| Caprice Resources Limited (CRS) ORDINARY FULLY PAID |
Materials |
$35 |
Cleansing Notice
|
20 Feb 2025 7:09PM |
$0.056 |
$0.053 |
fallen by
5.36%
|
|
| Moho Resources NL (MOH) ORDINARY FULLY PAID |
Materials |
$3 |
Results of General Meeting
|
20 Feb 2025 7:08PM |
$0.004 |
$0.004 |
fallen by
0%
|
|
| Pacgold Limited (PGO) ORDINARY FULLY PAID |
Materials |
$11 |
Amended Appendix 3X and Appendix 3Y
|
20 Feb 2025 7:07PM |
$0.069 |
$0.073 |
risen by
5.80%
|
|
| Caprice Resources Limited (CRS) ORDINARY FULLY PAID |
Materials |
$35 |
Application for quotation of securities - CRS
|
20 Feb 2025 7:06PM |
$0.056 |
$0.053 |
fallen by
5.36%
|
|
| Peak Minerals Limited (PUA) ORDINARY FULLY PAID |
Materials |
$53 |
Non-Renounceable Pro Rata Entitlement Issue Prospectus
|
20 Feb 2025 7:05PM |
$0.011 |
$0.019 |
risen by
72.73%
|
|
PUA - Price-sensitive ASX Announcement
Full Release
Key Points
- The Offer is a pro-rata non-renounceable entitlement issue.
- Eligible Shareholders can acquire 1 Share for every 10 Shares held.
- The issue price is set at $0.008 per Share.
- The Offer aims to raise up to $2,041,688.
- Eligible Shareholders have options to take up their Entitlement fully or partially.
- Non-participating Shareholders may face dilution of approximately 9.09%.
- All Shares issued will rank equally with existing Shares.
- The Prospectus is dated 20 February 2025 and includes important risk factors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| The Calmer Co International Limited (CCO) ORDINARY FULLY PAID |
Consumer Staple |
$6 |
Information on CCOAM Options Conversion
|
20 Feb 2025 7:04PM |
$0.006 |
$0.002 |
fallen by
66.67%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$8,710 |
Appendix 4G and 2024 Corporate Governance Statement
|
20 Feb 2025 7:03PM |
$26.460 |
$25.750 |
fallen by
2.68%
|
|
| Perpetual Equity Investment Company Limited (PIC) ORDINARY FULLY PAID |
Financials |
$467 |
Daily Net Tangible Asset Statement
|
20 Feb 2025 7:02PM |
$1.230 |
$1.220 |
fallen by
0.81%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$8,710 |
2024 Full Year Results Presentation
|
20 Feb 2025 7:02PM |
$26.460 |
$25.750 |
fallen by
2.68%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- FY2024 revenue increased by 56% to AU$783.2 million.
- Profit after tax improved 860% to AU$49.9 million.
- Operating cash inflow improved by 80% to AU$43.0 million.
- Cash balance increased significantly to AU$710.3 million.
- Illuccix® contributed to revenue growth in the PSMA market.
- Plans for multiple product launches in 2025.
- Ongoing pivotal trials for key therapeutic assets.
- Expansion into new markets including China and Japan.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$8,710 |
2024 Full Year Results Announcement
|
20 Feb 2025 7:01PM |
$26.460 |
$25.750 |
fallen by
2.68%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- Telix reported a record revenue of AU$783.2 million for FY2024, up 56% from 2023.
- The company experienced significant growth in profit after tax, increasing 860% to AU$49.9 million.
- Research and development investment for FY2024 was AU$194.6 million, focusing on late-stage assets.
- Three new products are planned for launch in 2025, along with the European rollout of Illuccix.
- Telix completed acquisitions of ARTMS, IsoTherapeutics, and RLS to enhance product delivery.
- FY2025 revenue guidance is set between AU$1.18 billion and AU$1.23 billion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$8,710 |
Appendix 4E and 2024 Annual Report
|
20 Feb 2025 7:00PM |
$26.460 |
$25.750 |
fallen by
2.68%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue increased to $783.2 million, a 56% rise from 2023.
- Net profit after tax rose to $49.9 million, significantly up from $5.2 million in 2023.
- The success of Illuccix® drove revenue growth.
- Telix is developing TLX101 for brain cancer treatment as part of its theranostic approach.
- New product launches planned for 2025 include TLX007-CDx and others.
- Telix expanded its manufacturing capabilities and footprint globally.
- The company is focused on precision medicine and innovative cancer treatments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PWR Holdings Limited (PWH) ORDINARY FULLY PAID |
Consumer Discretionary |
$662 |
PWR HY25 Investor Presentation
|
20 Feb 2025 6:56PM |
$8.390 |
$6.580 |
fallen by
21.57%
|
|
PWH - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue down 2.1% to $62.9m above guidance.
- NPAT down 58.3% to $4.1m above guidance.
- EBITDA down 40.2% to $11.0m.
- Aerospace & Defence revenue up 79%.
- Secured milestone A&D order valued at AUD 8.9m.
- New manufacturing facility in Stapylton expected to enhance efficiency.
- Investment in automated equipment and higher capacity.
- Focus on innovation with new product range commercialized.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PWR Holdings Limited (PWH) ORDINARY FULLY PAID |
Consumer Discretionary |
$662 |
Investments delivering outcomes that underpin future growth
|
20 Feb 2025 6:55PM |
$8.390 |
$6.580 |
fallen by
21.57%
|
|
PWH - Price-sensitive ASX Announcement
Full Release
Key Points
- PWR reported a net profit after tax of $4.1 million for H1 FY2025.
- A fully franked interim dividend of 2.00 cents per share will be paid on 21 March 2025.
- Aerospace and Defence revenue grew by 79% due to an increase in programs.
- Motorsport revenue increased by 5% driven by demand for emerging technologies.
- PWR is investing in a new headquarters and factories in Rugby and Indianapolis.
- The company expects FY2025 revenue to be 5-10% below FY2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Perenti Limited (PRN) ORDINARY FULLY PAID |
Materials |
$1,485 |
Ceasing to be a substantial holder
|
20 Feb 2025 6:55PM |
$1.390 |
$1.600 |
risen by
15.11%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
